Antisense oligonucleotide technology in the development of cancer therapeutics.
Tseng
B Y
BY
Genta Inc., San Diego, CA 92130, USA.
Brown
K D
KD
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001709:Biotechnology; D004247:DNA / Q000037:antagonists & inhibitors / Q000235:genetics; D004333:Drug Administration Routes; D015195:Drug Design; D004341:Drug Evaluation; D004345:Drug Industry; D004351:Drug Resistance / Q000235:genetics; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D009369:Neoplasms / Q000235:genetics / Q000628:therapy; D009374:Neoplasms, Experimental / Q000628:therapy; D009690:Nucleic Acid Conformation; D009693:Nucleic Acid Hybridization; D016376:Oligonucleotides, Antisense / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use*; D009857:Oncogenes / Q000187:drug effects; D012333:RNA, Messenger / Q000037:antagonists & inhibitors / Q000235:genetics; D011836:Radiation Tolerance / Q000187:drug effects / Q000235:genetics
D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; D004247:DNA